Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.1 USD | -0.21% | +0.48% | +0.55% |
Financials (USD)
Sales 2024 * | 604M | Sales 2025 * | 627M | Capitalization | 1.6B |
---|---|---|---|---|---|
Net income 2024 * | 14M | Net income 2025 * | -41M | EV / Sales 2024 * | 2.65 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.55 x |
P/E ratio 2024 * |
116
x | P/E ratio 2025 * |
-39.3
x | Employees | 652 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.98% |
Latest transcript on Supernus Pharmaceuticals, Inc.
1 day | -0.21% | ||
1 week | +0.48% | ||
Current month | -3.32% | ||
1 month | +0.80% | ||
3 months | +2.39% | ||
6 months | +6.09% | ||
Current year | +0.55% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Khattar
FOU | Founder | 62 | 05-03-29 |
Timothy Dec
DFI | Director of Finance/CFO | 66 | 21-08-22 |
Frank Mottola
CTO | Chief Tech/Sci/R&D Officer | 52 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Georges Gemayel
BRD | Director/Board Member | 64 | 15-03-22 |
Charles Newhall
CHM | Chairman | 79 | 05-03-29 |
John Siebert
BRD | Director/Board Member | 84 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.94% | 28 M€ | -0.48% | ||
0.94% | 14 M€ | -3.66% | ||
0.38% | 25 M€ | -1.43% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 29.1 | -0.21% | 625,388 |
24-05-16 | 29.16 | +1.46% | 1,090,039 |
24-05-15 | 28.74 | -0.79% | 381,638 |
24-05-14 | 28.97 | -2.39% | 557,388 |
24-05-13 | 29.68 | +2.49% | 549,388 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.55% | 1.6B | |
+16.03% | 79.03B | |
+10.23% | 8.96B | |
-10.76% | 5.19B | |
+51.58% | 4.77B | |
+12.50% | 4.26B | |
-20.70% | 2.37B | |
+12.83% | 2.3B | |
-29.65% | 2.21B | |
+19.51% | 2.17B |
- Stock Market
- Equities
- SUPN Stock